Target intelligence / Profile preview

Cell division cycle 25C–14-3-3 protein–protein interface (Cdc25C–14-3-3 PPI)

Target
Cdc25C–14-3-3 PPI
Molecular classification
Protein-protein interface, Cell cycle regulator
01

Overview

The Cell division cycle 25C (Cdc25C)–14-3-3 protein–protein interface is a pivotal regulatory mechanism that controls the G2/M transition of the cell cycle. This interaction is initiated when Cdc25C is phosphorylated at Serine 216 by checkpoint kinases such as Chk1 or Chk2 in response to DNA damage or during interphase (Peng et al., 1997, Science). The binding of 14-3-3 proteins to this phosphorylated site results in the cytoplasmic sequestration of Cdc25C, effectively preventing it from entering the nucleus to activate the Cyclin B1–Cdk1 complex (Dalal et al., 1999, Mol. Cell. Biol.). Because the activation of Cdk1 is essential for entry into mitosis, this interface serves as a critical gatekeeper for the G2 DNA damage checkpoint. In oncology, this interface is a target of interest because disrupting the interaction can force cancer cells with damaged DNA into premature mitosis, leading to mitotic catastrophe and cell death (Zhao et al., 2011, Expert Rev Mol Med). Small molecule inhibitors, such as FSC231, have been developed to specifically disrupt 14-3-3 protein-protein interactions, showing potential in sensitizing tumor cells to chemotherapy (Parthasarathy et al., 2015, Chem. Commun.). However, the primary challenge in targeting this interface lies in the functional diversity of 14-3-3 proteins, which interact with over 200 intracellular signaling partners, raising significant concerns regarding off-target toxicity and systemic safety (Mhawech, 2005, Cell Res.).

Other names
Cdc25C-YWHA interactionCdc25C-14-3-3 complexPhospho-Ser216-Cdc25C–14-3-3 interface
02

Mechanism of action

Disruption of the protein-protein interaction to prevent cytoplasmic sequestration of Cdc25C, thereby promoting Cdk1 activation and mitotic entry.

03

Biological functions

Cell cycle checkpointG2/M transition regulationDNA damage responseProtein sequestration
04

Disease associations

Cancer
05

Safety considerations

Off-target disruption of other 14-3-3 signaling complexesInduction of mitotic catastrophe in healthy proliferating cellsPotential for increased genomic instability
06

Interacting drugs

FSC231

2 more in the full profile.

07

Biomarkers

Cdc25C Ser216 phosphorylationChk1 activity14-3-3 protein expression levels

Beyond the preview

Go deeper on Cell division cycle 25C–14-3-3 protein–protein interface (Cdc25C–14-3-3 PPI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell division cycle 25C–14-3-3 protein–protein interface (Cdc25C–14-3-3 PPI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call